BIO.News Newsletter

USTR released its annual report on global IP protections—we take a closer look at what’s in it, and BIO’s take. Plus, we tell you why you should know about the lablab bean. (547 words, 2 minutes, 44 seconds)

Kicking off a new week and month with a recap of Friday’s AMR hearing, and a look at new biotech shirts on sale now at lululemon. (565 words, 2 minutes, 49 seconds)

Busy Friday: the PASTEUR Act was reintroduced yesterday, and a hearing today will look at the emerging threat of AMR. Plus, six things we’re watching on PBMs and a recap of yesterday’s hearing on patents and IP. (845 words, 4 minutes, 13 seconds)

A busy day on Capitol Hill advanced several BIO-backed bills that would help small biotechs, plus hearings that covered topics including PBMs, price controls, and 340B. (594 words, 2 minutes, 58 seconds)

BIO and KoreaBIO signed an MOU as part of the Korean President’s state visit. Plus, Washington’s talking about PBMs and BIO’s David Thomas takes a deep dive on the biotech market. (638 words, 3 minutes, 11 seconds)

Today’s new episode of the I am BIO Podcast explores the potential of biotech R&D in space, and we preview advice for biotechs on navigating the stormy market. (591 words, 2 minutes, 57 seconds)

Starting the week with a recap of Friday’s Supreme Court decision and what happens next, plus five cancer innovations BIO members announced at last week’s AACR annual meeting. (665 words, 3 minutes, 19 seconds)

Tomorrow is Earth Day, so we look at how biotech is already investing in our planet. Plus, Bio.News has an exclusive look at the state of AMR and how we can address it. (703 words, 3 minutes, 30 seconds)

News Alert: Supreme Court rules mifepristone will remain accessible during appeals process

Here’s what BIO told CMS about their drug price “negotiation” program, plus what Members of Congress and witnesses said on Capitol Hill yesterday about FDA’s authority and mifepristone, R&D tax credits, and 340B. (603 words, 3 minutes, 0 seconds)